Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

3500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-10

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to evaluate the accuracy of a novel molecular test for screening and monitoring endometrial lesions in women at medium-to-high risk for endometrial cancer.

The main questions it aims to answer are:

* What is the sensitivity and specificity of the CISENDO test (a DNA methylation test on cervical cytology samples) for detecting histologically confirmed endometrial intraepithelial neoplasia (EIN) or invasive endometrial cancer?
* How do DNA methylation levels change during the follow-up of endometrial lesions? Researchers will compare the results of the CISENDO test to the results from the standard diagnostic procedure (hysteroscopy with histology) to see if the molecular test can reliably identify high-risk lesions and track disease progression.

Participants will:

* Provide a residual liquid-based cervical cytology sample for the CISENDO test.
* Undergo a standard diagnostic hysteroscopy examination (with or without biopsy) for comparison.
* Some participants will return for follow-up visits at 6 and 12 months for repeat methylation testing and/or hysteroscopy to monitor their condition.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Neoplasms DNA Methylation Cervical Smears Early Detection of Cancer Endometrial Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Endometrial Cancer Risk Cohort

This is a prospective, observational cohort of women at medium-to-high risk for endometrial cancer. All participants undergo baseline cervical cytology sampling for DNA methylation testing (CISENDO) and diagnostic hysteroscopy. Follow-up strategy is stratified based on initial methylation results and risk factors, with some receiving repeat methylation testing and/or hysteroscopy at 6 and 12 months, and others receiving methylation testing only.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants must be 18 years of age or older.
2. Participants must possess medium-to-high risk factors for endometrial cancer as defined by Chinese consensus guidelines and are scheduled for hysteroscopic evaluation; OR are currently undergoing conservative treatment (e.g., progesterone therapy or endometrial ablation) for endometrial lesions, and have not received chemotherapy.
3. Participants must be capable and willing to provide written informed consent.
4. Participants must be willing to undergo at least one follow-up assessment within 1 year.
5. Participants must have an intact cervix (a history of LEEP or conization is acceptable).

Exclusion Criteria

1. Current treatment for any gynecologic malignancy other than endometrial cancer.
2. Current or untreated cervical, vaginal, or vulvar intraepithelial neoplasia or carcinoma.
3. History of total or subtotal hysterectomy, trachelectomy, radical trachelectomy, or pelvic radiotherapy.
4. Active lower genital tract bleeding.
5. Immunosuppressed state (e.g., HIV infection, status post organ transplantation).
6. Failure to undergo the planned hysteroscopic evaluation and follow-up within 1 year after the initial assessment.
7. Failed hysteroscopic procedure.
8. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lei Li

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Li Lei, Professor

Role: CONTACT

Phone: +86-139-1198-8831

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZS-2740

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

K9518

Identifier Type: -

Identifier Source: org_study_id